Author:
Muñoz-Chimeno Milagros,Valencia Jorge,Rodriguez-Recio Alvaro,Cuevas Guillermo,Garcia-Lugo Alejandra,Manzano Samuel,Rodriguez-Paredes Vanessa,Fernandez Beatriz,Morago Lucía,Casado Concepción,Avellón Ana,Ryan Pablo
Abstract
AbstractPoint of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.
Funder
This study was supported by the research contract MVP128/21 ISCIII-Abbott
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (2021).
2. WHO. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (2021).
3. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (2021).
4. Grebely, J., Dore, G. J., Morin, S., Rockstroh, J. K. & Klein, M. B. Elimination of HCV as a public health concern among people who inject drugs by 2030: What will it take to get there?. J. Int. AIDS Soc. 20, 22146. https://doi.org/10.7448/IAS.20.1.22146 (2017).
5. WHO. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-242016.246106-eng.pdf (2017).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献